Heart trial after breast cancer has ‘improved my life’

• Women completing breast cancer treatment can safely discontinue cardioprotective medications (likely ACE inhibitors/beta-blockers) without adverse cardiac outcomes, based on evidence from a 90-patient trial of cancer survivors.
• Stopping unnecessary long-term cardioprotective therapy after cancer treatment completion improves quality of life for survivors by reducing polypharmacy and associated side effects.
• Oncologists and cardiologists should consider deprescribing cardioprotective agents in asymptomatic breast cancer survivors once treatment is finished, rather than continuing indefinitely as standard practice.

Lucy Shepherd is one of 90 women to take part in a trial helping cancer survivors come off medication.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.